Hedge funds seize control of Mallinckrodt in latest case exposing flaws of US mass tort playbook
All of the swagger of the speciality pharma group has disappeared
Return of specific credit shocks jolts bond markets, led by energy sector
Big, lean dealmakers are reshaping the drugs industry — but are they running out of targets?